Platelet-specific antigen Sib' has been highly implicated in the pathogenesis of refractoriness to human leukocyte antigen (HLA)-matched platelet transfusions in Japan. We provide evidence that the Sib' antigen is located on the glycoprotein (GP) Iba and has a close association with the molecular weight (mol wt) polymorphism of GPlb. In modified antigencapture ELISA (MACE), anti-Sib' antibody reacted only with GPlb/lX held by a murine anti-GPlb/lX monoclonal antibody (MoAb). The reactivity of anti-Sib' antibody to Sib'-positive (Sib'+) platelets was abolished after they were treated with Serratia marcescens protease. Platelets from 50 healthy volunteers were semiquantitatively phenotyped for Sib' antigen by MACE and divided into three distinct groups: strongly NCOMPATIBILITY in platelet alloantigen systems leads I to various clinical disorders, such as posttransfusion purpura (PTP), neonatal alloimmune thrombocytopenic purpura (NATP),L32 and platelet transfusion refractoriness (PTR).3.4 Among the platelet alloantigens defined so far, Sib" antigen is most implicated in the pathogenesis of PTR in Japan? Phenotypic frequencies of platelet alloantigens differ considerably among various Although PIA1 alloantigen is most implicated in the pathogenesis of PTP and NATP among whites, no PIA heterogeneity has been reported among native Japanese. Another platelet alloantigen system, Pen6 or Yuk,' also located on glycoprotein (GP)IIIa*, where PIA antigens reside, is the most frequent cause of NATP in Japan.
important role as a frequent target antigen of antiplatelet autoantibodies in autoimmune thrombocytopenic purpura (AITP).'6317 In this report, we provide evidence that the Sib" antigen is located on the a-chain of GPIb and is closely associated with the mol wt polymorphism of GPIb.
MATERIALS AND METHODS
The antiserum containing anti-Sib" antibody used in this study was from the proband reported by Saji et aL3 Antisera specific for Brb and PIA' alloantigen were gifts from Dr C. Mueller-Eckhardt (GieBen, Germany) and Dr T.J. Kunicki (Mil- waukee, WI), respectively.
Murine monoclonal antibodies (MoAbs) SZ1 (specific for GPIbIIX complex") and SZ2 (specific for GPI~CC'').~) were purchased from Immunotech (Marseille, France). TP 80 (specific for GPIIb), 4B4 (specific for GPIIa), and OKM5 (specific for GPIV) were obtained from Nichirei (Tokyo, Japan), Coulter (Hialeah, FL), and Ortho Diagnostic System (Beerse, Belgium), respectively. AP1 (specific for GPIbaI4) was also a gift from Dr T. J. Kunicki. Venous blood was drawn from healthy volunteers into acid-citrate-dextrose [ACD, National Institutes of Health (NIH) formula A] and centrifuged at 250g for 10 minutes at ambient temperature. The obtained platelet-rich plasma (PRP) was mixed with 20 ng/mL prostaglandin E, (PGE,, Sigma, St Louis, MO) and then further centrifuged at 750g for 10 minutes. The platelet pellets were washed three times in Ringer's citrate dextrose buffer (RCD pH 6.5) containing 20 nglmL PGE, and 10 mmol/L Na,EDTA, and finally resuspended in any desired buffer.
Fifty microliters of a murine antiplatelet MoAb in carbonate buffer (pH 9.6) at a concentration of 3 pg/mL was added to each well of a microtiter plate (Immuno Module, Nunc, Roskilde, Denmark) and incubated overnight at 4°C. The wells were washed once with phosphatebuffered saline (pH 7.4) containing 0.05% Tween 20 (PBS/Tween) and blocked with the same buffer for 30 minutes at ambient temperature.
Washed platelets were resuspended in PBS/10 mmol1L Na,EDTA (PBS/EDTA), and the count was adjusted to 109/mL. One hundred microliters of each platelet suspension was mixed with 5 to 20 p L sera containing antiplatelet alloantibodies and incubated for 60 minutes at ambient temperature. The sensitized platelets were washed twice in PBSIEDTA, resuspended in 90 pL PBS/EDTA and solubilized by addition of 10 p1 10% Triton X-100 (Nacalai Tesque, Kyoto, Japan) . The lysate was kept on ice for 15 minutes with occasional vortexing and then centrifuged at 11,750g for 15 minutes to pellet insoluble materials. The resultant supernatant was added to each well of the microtiter plates in duplicate Antibodies.
Platelet isolation.

Modified antigen-capture ELISA (MACE).
and incubated for 60 minutes. After five subsequent washes, the F(ab'), fraction of biotinylated goat anti-human IgG (Tago, Burlingame, CA) diluted 1:3,000 in PBS/Tween was added and the plate was incubated for 60 minutes. Each well was washed five times and further incubated with alkaline phosphatase-streptavidin (Zymed, South San Francisco, CA) diluted 1:2,500 in PBS/Tween for 30 minutes. After six additional washes, p-nitrophenylphosphate in 0.9 mol/L diethanolamine buffer (pH 9.8) containing 0.5 mmol/L MgCI, was added and the plate was allowed to develop color for 30 minutes at ambient temperature. Absorbance at 405 nm was recorded using a microplate reader (Bio-Rad Novapath Microplate Reader, Bio-Rad, Richmond, CA).
Background absorbance varied depending on the capturing MoAbs used in each assay; mean optical density of negative controls was SZ1, 0.324; 4B4, 0.176; TP80, 0.103; and OKM5, 0.102. The results of each assay were indicated for clarification by the optical density ratio (OD ratio) calculated by the following formula: O D ratio = (OD of a sample -mean O D of negative controls)/mean O D of negative controls.
Platelets were acid treated by the method of Kurata et al?'~22 to remove antigenicity of human leukocyte antigen (HLA) class I antigens expressed on platelets. Washed platelets were resuspended in acid solution [132 mmol/L citric acid, 67 mmol/L Na,HPO,, 0.1% bovine serum albumin (BSA), pH 3.01 for 10 minutes on ice and then immediately neutralized with an excess of citrate buffer, pH 6.5.
Acid-treated platelets were resuspended in PBS/EDTA at a concentration of 108/mL. One hundred microliters of this suspension was incubated with appropriately diluted antiplatelet alloantibodies or murine MoAbs for 1 hour at ambient temperature. After washing with PBS/EDTA, the platelets were further incubated with 100 KL appropriately diluted FITCconjugated goat F(ab')z anti-human IgG (Tago) or anti-mouse IgG (Becton Dickinson, San Jose, CA) for 30 minutes in the dark. After washing, samples were analyzed on an EPICS V analyzer (Coulter). Optimal conditions for each antiplatelet antibody to yield maximum fluorescence intensity were determined individually. In subsequent studies, the effect of protease from Serratia marcescens on the binding of anti-Sib" antibody was investigated using flow cytometry. Sib"+ platelets were treated with S marcescens protease (a gift from Takeda Phamaceuticals, Tokyo, Japan) at a final concentration of 24.9 U/mL for 5 minutes at 37°C. The platelets were washed in PBS/EDTA to stop the enzyme cleavage and then acid treated. Flow cytometric analyses were made as described above.
Washed platelets were resuspended at 5 X 109/mL in PBS/EDTA containing 1 mmol/L phenylmethylsulfonyl fluoride (Sigma) and mixed with %O vol 10% Triton X-100 in PBS on ice. After occasional vortexing, the lysate was centrifuged at 11,750 g for 15 minutes. The supernatant was mixed with an equal volume of sample buffer [4% sodium dodecyl sulfate (SDS) in 50 mmol/L Tris-HC1 (pH 6.5) containing either 10% 2-mercaptoethanol or 20 mmol/lN-ethylmaleimide] and incubated at 56°C for 30 minutes. Approximately 100 kg total protein from each platelet preparation was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli,zl with a 5% homogeneous slab gel. Electrophoresed GPIb and other GPs were visualized by periodic acid-silver staining according to the method of Dubray." Gels were soaked in fixing solution [25% (vol/vol) isopropyl alcohol/ 10% acetic acid] at ambient temperature overnight. The gels were soaked in 7.5% acetic acid, incubated in 8.8 mmol/L periodic acid at 4°C for 60 minutes, washed for 3 hours in distilled water, and then transferred into freshly prepared ammoniacal silver solution (112 mmol/L ammonium hydroxide, 45.7 mmol/L silver nitrite, Acid treatment.
Flow cytomety.
Gel electrophoresis and periodic acid-silver staining. and 18.9 mmol/L sodium hydroxide). After 40-minute incubation with constant shaking, the gels were rinsed for 2 minutes in distilled water and transferred to freshly prepared developing solution [23.8 mmol/L citric acid, 6.33 mmol/L formaldehyde, and 10% (vol/vol) methanol]. Development was stopped by rinsing the gels in photography fixative and washing them in distilled water.
To identify GPIb on periodic acid-silverstained gels, we performed immunoblotting with SZ2 as a probe. Platelet proteins were separated by SDS-PAGE and electrotransferred to PVDF membrane (Immobilon P, Millipore, Bedford, MA) according to the manufacturer's instructions. The PVDF membrane was cut into strips and soaked in 5% (wtlvol) skim milk in PBS/Tween for 1 hour to block unreacted sites. The strips were washed twice in PBS/Tween and incubated with SZ2 at a concentration of 2 pg/mL in PBS/Tween containing 0.5% skim milk for 1 hour. After three washes, the strips were further incubated with alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma) diluted 1:2,000 in PBS/Tween containing 0.5% skim milk. After final three washes in PBS/Tween, the color was developed in the presence of both 0.33 Kg/mL nitro blue tetrazolium (Sigma) and 0.165 pg/mL 5-bromo-4-chloro-3-indolyl phosphate (Sigma) in 100 mmol/L Tris-HC1, pH 9.5, containing 100 mmol/L NaCl and 5 mmol/L MgCl,.
Washed intact platelets (3 x lo8) were suspended in 300 p L PBS/EDTA and incubated with antiplatelet antibodies for 120 minutes at ambient temperature. After two washes with PBS/EDTA, the sensitized platelets were solubilized in 1% Triton X-100 for 15 minutes at 4°C. Each lysate was centrifuged at 11,750gfor 15 minutes, and the supernatant was incubated with a slurry of Protein A-Sepharose CL-4B (PAS, Sigma) for 90 minutes with continuous gentle shaking to isolate immune complexes. The PAS beads were washed five times in PBS/Tween, resuspended in 50 pL SDS-PAGE sample buffer, and incubated at 56°C for 30 minutes. The samples were separated by SDS-PAGE and transferred to PVDF membrane. Immunoprecipitated GPIb fixed on the membrane was detected by immunoblotting with SZ2 as the probe.
Washed platelets were treated with neuraminidase according to the method described by Take et aLZ5 Platelets were suspended in 0.5 mol/L citrate buffer (PH 6.2) and mixed with neuraminidase (Nacalai Tesque) at a final concentration of 0.5 U/mL at 37°C for 3 hours. The digestion was stopped by washing the platelets twice with PBSIEDTA. Neuraminidase-treated platelets were immunoblotted to examine the effect of the digestion on the mol wt polymorphism of GPIb. Binding of anti-Sib" antibody to the neuraminidasetreated GPIb was also investigated with MACE.
Immunoblotting.
Immunoprecipitation and identification of GPIb.
Neuraminidase treatment of washed platelets.
RESULTS
With MACE, target platelet GPs to which platelet alloantibodies bound could be easily identified. As shown in Fig 1, anti-Sib" IgG bound specifically t o the GPs held by SZ1, which was specific for GPIb/IX complex. On the other hand, anti-Brb and anti-PIA' IgG reacted only with the GPIa/IIa complex bound by 4B4 and the GPIIb/IIIa complex bound by TP80, respectively. Anti-Sib" antibody did not react with GPs bound by 4B4, TP80, or OKM5 (specific for GPIV). The data shown in Fig 1 represent typical results from three independent experiments. With this assay with SZ1, platelets from 50 unrelated healthy Japanese volunteers were phenotyped for Sib". Fifteen of the volunteers (30%) were positive for Sib" antigen (Sib"). Among those, platelets from three individuals bound high
MACE.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Flow cytometry. Preliminary experiments showed that incubation of anti-Sib" antibody at a dilution of 1:20 with Sib" strongly positive (group 1) platelets resulted in maximum fluorescence intensity in flow cytometry (data not shown). Therefore, these conditions were used for all three groups. Platelets were always acid treated to eliminate the interaction between HLA class I antigens on platelets and high-titered anti-HLA antibodies contained in the antisera. Without the acid treatment, Sib"-platelets showed strong reactivity with the anti-Sib" antisera but no reactivity after the acid treatment, indicating that the antigenicity of HLA antigens was eliminated sufficiently for subsequent analyses (data not shown). Group 1 platelets bound larger amounts of antisib" antibody detected in flow cytometry than did group 2 platelets (Fig 2A) . An anti-GPIb MoAb, SZ2, bound equally to the platelets from all three groups, however, indicating that an equal amount of GPIb was expressed on all platelets (Fig 2B) . Apparent differences in the amount of bound IgG to the group 1 platelets between anti-Sib" (Fig 2A) and SZ2 (Fig 2B) could be attributed to the difference in the molar FITC/protein ratio of the second antibody used in each assay.
Subsequently, the effect of S marcescens protease on binding of various antiplatelet antibodies to group 2 platelets was investigated in flow cytometry (Fig 3) . Both antisib" and SZ2 binding was abolished. On the other hand, reactivity of the protease-treated platelets with anti-PIA', TP80, and SZ1 was unchanged. Mol wtpolymorphism of GPIb. Platelets phenotyped for Sib" were next analyzed by SDS-PAGE and periodic acidsilver staining for the mol wt polymorphism described by Moroi et a1.l' One or two darkly stained band(s) with apparent mol wt ranging from 163,000 to 152,000 were observed in each platelet preparation under nonreducing conditions (Fig 4A) . Platelets from any single donor did not concurrently show three or more darkly stained bands with apparent mol wt in this range. That these bands were GPIb was verified by immunoblotting with SZ2 as the probe (Fig  4B) . All four phenotypes of GPIb designated by Moroi et allo were identified in platelets from the 50 individuals. The apparent mol wt of each GPIb phenotype under nonreducing conditions was about 163,000, 160,000, 155,000, and 152,000 for A, B, C, and D, respectively. The frequency of each GPIb phenotype among the 50 individuals is summarized in Table 1 .
Association of Sib" antigen with the mol wtpolymorphism of GPZb. The relationship in each platelet preparation between the reactivity with the anti-Sib" antibody (represented by groups 1 through 3) and the mol wt phenotype of GPIb is summarized in Table GPIb phenotypes were positive for Sib" according to MACE. These observations indicated that the Siba antigen is closely associated with the mol wt polymorphism of GPIb.
To confirm that only A and B phenotypes of GPIb carry the Sib" epitope, 3H-labeled platelet GPs were immunoprecipitated with antiplatelet antibodies. Although anti-PIA1 and SZ2 immunoprecipitated 3H-labeled corresponding antigens, antiSib" antibody immunoprecipitated only HLA class I molecules (data not shown). Loss of Sib" antigenicity during 3H-labeling procedure by periodatelborohidride was suspected, and an immunoprecipitation procedure with unlabeled platelets as the source of antigens was designed. AP1 immunoprecipitated all GPIb phenotypes (Fig 5, lanes 1,  3, 6, and 9) . On the other hand, the anti-Sib" antibody specifically immunoprecipitated the higher mol wt forms of GPIb, A and B (Fig 5, lanes 4,7, and 10) .
Neuraminidase treatment of platelets. Because GPIb is very rich in involvement of the carbohydrate moiety in both expression of Sib" antigen and the mol wt polymorphism was suspected. Platelets were treated Immunoprecipitation of unlabeled GPZb. log fluorescence with neuraminidase to investigate this possibility. The apparent mol wt of all GPIb phenotypes, determined by immunoblotting with SZ2 as the probe, decreased significantly (Fig 6) . The extent of this reduction was larger in smaller GPIb phenotypes; approximately 5,000 daltons in C and D phenotypes v 2,000 daltons in A and B phenotypes under reducing conditions. Of note are the results from MACE indicating that the binding of anti-Sib" antibody to Sib"' (group 2) platelets was significantly augmented by neuraminidase treatment of the target platelets; the OD ratios (mean ? SD) of untreated platelets v treated platelets were 2.72 ? 0.44 and 3.70 ? 1.03 (n = 6, P < .05),
respectively.
Family studies on inheritance of Sib" antigen and mol wt polymorphism of GPlb. Three families were analyzed regarding the inheritance of Siba antigen and the mol wt polymorphism of GPIb. Figure 7 shows pedigrees of two of the three families. These studies confirmed that the inheritance pattern of both Sib" antigen and the mol wt polymorphism showed autosomal (co) dominant traits and that the expression of Sib" antigen was always linked to the A 
DISCUSSION
Platclct Sib' antigcn, first dcscribcd by Saji ct al,' was dcfincd by an antibody dctcctcd in thc scrum of a patient who had bccomc refractory to both random and HLAmatched platclct transfusions. In this report, wc provide scvcral lines of cvidcncc indicating that thc Sih" antigcnic dctcrminant is locatcd on thc a-chain of GPlb and that it is closcly associatcd with thc mol wt polymorphism of GPIb.
Localization of Sib' antigen to GPIba was dcmonstratcd by two lincs of cvidcncc. First, with MACE, in which murinc MoAbs spccific for platclct mcmbranc GPs (including SZ1, TPXO. 4B4. and OKMS) wcrc uscd, anti-Sib' spccifically rcactcd with thc GPlb/lX complcx bound to SZ1. Anti-Sib' did not rcact with thc GPllb/llla complcx bound to TP80, GPIa/lIa (or GPWlla) complcx bound to 4R4. or with GPlV bound to OKMS. In othcr cxpcrimcnts in which SZ1 was rcplaccd by othcr anti-GPlb MoAbs. such as SZ2 and API, anti-Sib' also rcactcd with thc bound GPs (data not shown). Second, reactivity of antisib" and SZ2 to Sib" platclcts assayed by flow cytomctry was abolishcd aftcr trcatmcnt of thc platclcts with S marcescens protcasc, whcrcas binding of anti-PI'", TP80, and SZ1 rcmaincd unchanged. Platclcts trcatcd with S marce.mw protcasc lost thcir reactivity with a murinc MoAb spccific for thc peptide tail rcgion of GPIb, SZ2, but not with another murinc MoAb spccific for thc mcmbranc-associated rcgion of GPlb/lX, SZ1. In addition, rclcasc of most of thc glycocalicin on thc surfacc of digcstcd platclcts to thc supcrnatant undcr thcsc conditions was confirmed by immunoblotting (data not shown). Thcsc ohscrvations arc in accord with previous reports''.'' that S marce.mvw protcasc spccifically clcavcs GPIb to rclcasc glycocalicin and thcrcforc strongly indicate that anti-Sib' is bound to a dctcrminant on thc S marce.mws protcasc-scnsitivc rcgion of GPIb, glycocalicin.
Kuijpcrs ct all' rcportcd that Ko'/Koh alloantigcns wcrc From our data, wc calculatcd thc phcnotypic frcqucncy Platclcts from 50 donors wcrc divided into thrcc groups ( I , 2. and 3) according to thcir rcactivity with anti-Sib' dctcr- 21, A/A (lanes 3  through 5) . A/C (lanes 6 through 8). and B/D (lanes 9 through 11). Antibodies were a murine MoAb anti-GPlba. AP1 (lanes 1, 3, 6 , and 9). anti-Sib' (lanes 2, 4, 7, and lo), and negative control sera Although a mol wt polymorphism of GPIb was noted before in two patients with a bleeding diathe~is,'~ Moroi et all0 first reported the existence of the genetic polymorphism of GPIb among healthy Japanese individuals. According to its apparent mol wt, each GPIb phenotype was designated A, B, C, and D (A is the largest). No individuals with any combination of GPIb phenotype showed bleeding or thrombotic diathesis. In an aggregation study, platelets with any combination of GPIb phenotype responded equally well to thrombin, ADP, and ristocetin." Since then, this polymorphism has been reported among various With SDS-PAGE and periodic acid-silver staining, we identified these four phenotypes of GPIb in platelets from 50 healthy Japanese donors. The identity of GPIb stained by periodic acid-silver staining was verified by immunoblotting with SZ2 as the probe. Phenotypic frequencies of the mol wt polymorphism of GPIb obtained from our study significantly differed from those in previous report~.'~~''~~" We noted three individuals with A/A phenotype in 50 unrelated volunteers whereas no other previous reports documented their existence. These discrepancies could be attributed to differences in ethnic and regional backgrounds. The expression of KO" antigen, serologically similar to Sib" antigen, among whites is significantly lower than that of Sib" in Japan" (14.3% v 25.4%).
Analysis of the relationship between the Sib" phenotype and the mol wt phenotype of GPIb showed a perfect association of Siba antigen with the higher mol wt phenotypes of GPIb, A and B. Group l platelets showed the A/A phenotype without exception, whereas group 2 platelets showed A or B plus C o r D. All Siba-platelets were of C/C, C/D, or D / D phenotypes. Individuals with an A/B or B/B phenotype, which would also be Sib" strongly positive, have not yet been found.
The association of Siba antigen with the mol wt polymorphism was then directly demonstrated by immunoprecipitation. An MoAb specific for GPIba, AP1, immunoprecipitated all GPIb phenotypes. In contrast, anti-Sib" antibody specifically immunoprecipitated the higher mol wt phenotypes of GPIb, A and B, from the lysate of unlabeled platelets. Immunoblotting was also performed to confirm further the results of immunoprecipitation, but anti-Sib" antibody failed to react with SDS-denatured GPIb.
These observations indicated that Sib" antigen was located solely on the A and B phenotypes of GPIb and that the 5-Kd fragment accounting for the difference in size between B and C phenotypes might contribute to Sib" antigenicity.
In a previous study,'" neuraminidase treatment of platelets appeared to have no effect on the mol wt polymorphism of GPIb. In our experiments in which platelets were treated with a higher concentration of neuraminidase, the apparent mol wt of all GPIb phenotypes significantly decreased. The reduction in size was greater in the smaller phenotypes, C and D, than in the larger A and B; 5,000 daltons in C and D v 2,000 daltons in A and B. Satisfactory removal of sialic acid was also confirmed by enhancement of the reactivity of Ricinus communis aggulutinin (RCA) I lectin with neuraminidase-treated GPIb demonstrated by lectin-blot assay (data not shown). These data led us to consider that not only primary structures but also carbohydrate moieties were responsible for the difference in mol wt of GPIb. This hypothesis was also supported by recent report of Meyer and Schellenberg" that the C-terminal region of glycocalicin (macroglycopeptide), rich in carbohydrate, contributed to these mol wt polymorphisms of GPIb." Binding of antisib" antibody to Siba+ platelets determined by MACE was augmented by neuraminidase treatment of the platelets. These results suggested that expression of Siba antigen did not depend directly on the presence of sialic acid and that the Sib" antigen would become more accessible by conformational and/or an electric change induced by removal of sialic acid.
The nature of the Sib" antigen is different from that of the PIA and Bak alloantigen systems in that the 5-Kd fragment of GPIba, which accounts for the difference in mol wt between type B and type C, would be responsible for the expression of Sib", whereas only a single base change (resulting in a single amino acid change) differentiates each allele in the PIA and Bak
One newly defined platelet antigen, Nap, is localized to GPIV34 and has recently been proven an isoantigen because Nap-platelets appeared to lack GPIV.35 Sib"-platelets have the normal number of fully functioning GPIb molecules. This type of alloantigen has not been reported in the field of platelet immunology and would serve as an ideal model to investigate the evolution of an essential platelet GP, GPIb.
